Evidence map›Paper›PMID 40242041›Full record

ArticleACS applied nano materials2025

Extracellular Vesicle-Liposome-Darunavir Formulation for the Treatment of HIV Neuropathogenesis.

Lina Zhou, Sandip Godse, Namita Sinha, Dejian Ma, Golnoush Mirzahosseini, Mohd Salman, Paul Pulliam, Chalet Tan, Udai P Singh, Tauheed Ishrat and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied nano materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lina ZhouDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Sandip GodseDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Namita SinhaDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Dejian MaDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Golnoush MirzahosseiniDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Mohd SalmanDepartment of Anatomy and Neurobiology, College of Medicine, The University of Tennessee Health Science Center, 875 Monroe Avenue, Memphis, Tennessee 38163, United States.
Paul PulliamPlough Center for Sterile Drug Delivery Solutions, University of Tennessee Health Science Center, 208 South Dudley Street, Memphis, Tennessee 38163, United States.
Chalet TanDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Udai P SinghDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Tauheed IshratDepartment of Anatomy and Neurobiology, College of Medicine, The University of Tennessee Health Science Center, 875 Monroe Avenue, Memphis, Tennessee 38163, United States.
Harry KochatDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.
Santosh KumarDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, Tennessee 38163, United States.ORCID https://orcid.org/0000-0001-7846-5674

Funding

Extracellular vesicles in AD-like pathology in HIV and its potential therapeuticsR21AG081140 · NIA · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ISHRAT, TAUHEED, KUMAR, SANTOSH · 2023 to 2024
$424k
Extracellular vesicles-based drug delivery of antiretroviral regimen to target CNS HIV reservoirsR21MH125670 · NIMH · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI KUMAR, SANTOSH · 2021 to 2022
$424k
NIA NIH HHS R21 AG081140NIMH NIH HHS R21 MH125670
6 · The paper itself

Abstract

This study evaluates the efficacy of an extracellular vesicles-liposome-darunavir (EV-Lip-DRV) formulation for the treatment of HIV neuropathogenesis, including neurocognitive disorders. The EV-Lip-DRV formulation was developed through a process involving thin-film hydration and extrusion, followed by ultrafiltration to remove unloaded DRV. The encapsulation efficiency was found to be 41.75 ± 2.19%, with a particle size of ∼189 nm and zeta potential of ∼-7.8 mV. The hemocompatibility test confirmed the safety of the formulation for red blood cells, while drug release profiles demonstrated a sustained release of DRV within 24 h. Our

Identifiers

PMID40242041
PMCPMC11997951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.